Submitted by Viatris
Our work to respond to emergent needs from the COVID-19 pandemic offers important examples of our commitment to partnership in pursuit of equitable access.
In India, where Viatris has a substantial manufacturing and employee footprint, we created a 360-degree partnership ecosystem with central government, state governments, public and private hospitals, academic and research institutions, NGOs and other pharmaceutical companies to ensure uninterrupted access to high-quality COVID-19 treatments. We worked closely with
the government of India, particularly the Ministry of Health & Family Welfare and Department of Pharmaceuticals, and extended our full support to the government COVID-19 response, including by maintaining adequate stocks of needed medicines while also pursuing export licenses to enable access to our medicines made in India for patients across the world.
In Thailand, the Philippines, Vietnam, Indonesia, Myanmar, Cambodia, Laos, Sri Lanka, Nepal and Mongolia, a special cross-functional task force called the CARE Team - COVID-19 Alleviation Response - was formed to actively aid in expanding access to needed medicines.
During the peak of the pandemic in these countries, there were about 300,000 COVID-19 cases on any day. Viatris stepped in at this critical moment and provided widespread and cost efficient access to remdesivir and molnupiravir by working with governments and other relevant stakeholders, enabling export of these medicines from India to meet patient needs. We supplied a total of 2.5 million vials of Desrem™ (remdesivir) and 40 million capsules of Molnatris™ (molnupiravir) across these countries. In total, the treatments reached about 1.5 million patients in this region.
Because we know that access is about more than supplying medicines, we also provided information to hospitals and healthcare providers via webinars and partnerships with medical societies and local governments. Also, we maintained a 24-7 toll-free helpline number for patients in India to advise on the availability of medicines.
Addressing the Effects of the COVID-19 Pandemic
Although COVID-19 infections are growing less deadly as populations develop greater immunity, the impacts of the pandemic are still being felt. The pandemic revealed stark inequities in care in and between countries, strained healthcare systems, left chronic conditions undiagnosed or poorly treated and underscored the huge importance of strong supply chains prepared for future global
health emergencies. Viatris continues to seek to understand the challenges faced by people and systems and to co-create solutions that advance us collectively toward the shared objective of equitable, sustainable access.
A prominent element of the conversation centers on how to ensure availability of essential medicines. Thanks to our large and diverse supply network, we have been able to address some of the causes and apply solutions for supply disruption. The global network that Viatris sources from, both internally and externally, is a true asset in ensuring agile and responsive supply targeted to emerging needs. Moving medicines across borders quickly and safely is critical to ensure access where it is most needed, especially in pandemic settings when countries may be at different phases of infection waves and face rapidly evolving needs.
Building Pandemic Preparedness
We are working with stakeholders across the globe to prepare for future pandemics. The work includes understanding how healthcare providers and systems can better help patients and respond to the needs of communities.
Building resilient health systems that can meet patient needs on an ongoing basis and respond rapidly and equitably to surges of infectious disease is critical. Our diverse efforts to advance this preparation include the following:
1The Global Fund
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris’ portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, and a variety of over-the-counter consumer products. With more than 38,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn, Instagram and YouTube.
More from Viatris